MARKETS / NASDAQ / SNDX

NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Syndax Pharmaceuticals Inc. SNDX

12 fiscal years on record · USD · FY2025 reported · SEC filings only

Revenue

$172.4M

▲ 627.8% YoY

Net income

$-285.4M

Free cash flow

$-323.2M

In brief

What this company does

Niktimvo (axatilimab-csfr) is a colony stimulating factor-1 receptor blocking antibody that was approved by the FDA in August 2024 for chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg. The company leads the commercialization and further development of revumenib and works with its collaboration partner, Incyte, on the commercialization and further development of axatilimab. As of February 16, 2026, it had 277 full-time employees, of whom 128 were primarily engaged in research and development activities. The company currently operates in one segment. Its principal office is located in New York, New York, where it leases approximately 12,000 square feet of office space under a lease that expires in August 2028. Syndax Pharmaceuticals, Inc. was incorporated in Delaware in 2005.

Written from the business description in Syndax Pharmaceuticals Inc's annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth

USD 172.4M

Revenue, FY2025 · full 12-year series below

Revenue $M Net income $M

FY2025 · Revenue 172.4 · Net income -285.4

Compound annual growth

Revenue

+157.7%

+75.4%

3 yrs

5 yrs

10 yrs

15 yrs

Revenue compounded at +157.7% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−166 cents

lost on every revenue dollar

Operating margin Net margin

FY2025 · Operating -158.4% · Net -165.6%

ROE

FY2025 · ROE -161.8%

Gross margin—

Operating margin-158.4%

Net margin-165.6%

Return on assets-45.5%

EBITDAUSD -267.1M

Each USD of equity lost 162 cents this year.

Cash & shareholders

—

returned in FY2025 · dividends + net buybacks

Free cash flow $M

FY2025 · FCF -323.2

Total assetsUSD 529.7M

EquityUSD 64.6M

CashUSD 134.9M

Gross debtUSD 350.0M

Net debtUSD 215.1M

Current ratio4.40×

Net debt stands at 333% of equity.

The 12-year record

12 fiscal years

Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue $B	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	·
Operating income $B	−0.3	−0.3	−0.2	−0.2	0.0	−0.1	−0.1	−0.1	−0.1	−0.0	−0.0	−0.0
EBITDA $B	−0.3	−0.3	−0.2	−0.1	0.1	−0.1	−0.1	−0.1	−0.1	−0.0	−0.0	−0.0
Income tax $B	0.0	·	·	·	0.0	0.0	0.0	0.0	0.0	0.0	0.0	·
Net income $B	−0.3	−0.3	−0.2	−0.1	0.0	−0.1	−0.1	−0.1	−0.1	−0.0	−0.0	−0.0
Free cash flow $B	−0.3	−0.3	−0.2	−0.1	0.0	−0.1	·	−0.1	−0.0	−0.0	−0.0	−0.0
EPS, diluted $	−3.29	−3.72	−2.98	−2.46	0.46	−1.87	−1.84	−2.92	−2.90	−3.22	−1519.27	−453.02
Dividend / sh $	·	·	·	·	·	·	·	·	·	·	·	·
Payout %	·	·	·	·	·	·	·	·	·	·	·	·
ROE %	−161.8	−75.7	−41.0	−34.1	7.5	−51.6	−132.4	−94.0	−64.5	·	·	·
Shares out B	0.09	0.09	0.08	0.07	0.05	0.05	0.03	0.02	0.02	0.02	0.00	·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance

Company facts, as filed

How we verify · 0 failures in 46 reconciliationsAUDITED

Reconciled in 12 of 19 fiscal years. 30 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures

ActivityPharmaceutical Preparations

Listed onNASDAQ

Incorporated inDelaware

Fiscal year endsDecember 31

Data on record since2014